CN105503880A - Medicine composition for treating respiratory diseases - Google Patents
Medicine composition for treating respiratory diseases Download PDFInfo
- Publication number
- CN105503880A CN105503880A CN201510929933.3A CN201510929933A CN105503880A CN 105503880 A CN105503880 A CN 105503880A CN 201510929933 A CN201510929933 A CN 201510929933A CN 105503880 A CN105503880 A CN 105503880A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- respiratory tract
- tract disease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for treating respiratory diseases. The medicine composition comprises an effective dose of compound and a carrier capable of being accepted pharmaceutically. The compound has the following structure shown in the description. The compound has the remarkable effect on pathogenic bacteria causing the respiratory diseases and can be developed into the novel clinically-effective medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of respiratory tract disease.
Background technology
Respiratory tract disease mainly comprises asthma, tonsillitis, pharyngitis, bronchitis etc., the sickness rate of these diseases above-mentioned is higher, mainly adopt western medicine at present, in western medicine scheme, the overwhelming majority must use antibiotic, and these diseases are diseases of easy recurrent exerbation, cause the use rank of antibiotic more and more higher.But the harm of well-known antibiotic is again ubiquitous, and investigation shows: children applied antibiotic after 5 months, infects resistance probability and rise to 100%, accept the patient of more than 5 kinds antimicrobial drugs, concurrent medicine poison reactivity is up to 80%; Antibiotic is used to cause the Childhood that about 60% patient in 2,000,000 the deaf-mutes of the whole nation being, therefore, the Ministry of Health put into effect " antimicrobial drug Clinical Management method " the tightest in history on October 14th, 2011, carries out focus efforts on special areas, limit antibiotic abuse with this use of antibiotic.But antibiotic is abused phenomenon and is not fundamentally improved so far.The mutation of anti-medicine bacterium emerges in an endless stream, and the antibiotic newly developed, vaccine cannot catch up with the speed of mutation of anti-medicine bacterium.And abuse the avalanche in microorganism species imbalance that antibiotic causes and the anti-throat that medicine bacterium is spread unchecked, environment pollution causes, tracheal wall mucosal tissue structure chronic nonspecific inflammation pathology and the endogenous immunizing power of bringing out, resistibility defence line, make the diagnosis of respiratory system disease easy, the phenomenon that radical cure is difficult to cannot solve always.
Respiratory tract disease is current common clinical, and respiratory tract disease majority is caused by pathogenic bacterium, finds that in the recent period pseudomonas aeruginosa ATCC9027 is also one of germ wherein.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of respiratory tract disease.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of respiratory tract disease, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of respiratory tract disease, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment respiratory tract disease, and this compound has having structure:
Preferably, described infection is caused by pseudomonas aeruginosa ATCC9027.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition pseudomonas aeruginosa ATCC9027, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing stomach and intestine, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition pseudomonas aeruginosa ATCC9027
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination bacterial classification pseudomonas aeruginosa ATCC9027 purchased from Bei Nuo bio tech ltd, Shanghai.
Nutrient solution
Nutrient agar medium and nutrient broth, purchased from Chen Yu experimental installation company limited of BeiJing ZhongKe.
Test method
Pseudomonas aeruginosa ATCC9027 is inoculated in agar plate nutritive medium plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 18000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritive medium plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The mean diameter of the bacterial restrain of pseudomonas aeruginosa ATCC9027 is 13.69mm, and this shows that target compound has the effect of extremely strong vitro inhibition pseudomonas aeruginosa ATCC9027.
Claims (9)
1. treat a compound for respiratory tract disease, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for respiratory tract disease, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of respiratory tract disease according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of respiratory tract disease according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of respiratory tract disease according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of respiratory tract disease according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment respiratory tract disease, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by pseudomonas aeruginosa ATCC9027.
9. the purposes of compound in the medicine of preparation vitro inhibition pseudomonas aeruginosa ATCC9027, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510929933.3A CN105503880A (en) | 2015-12-15 | 2015-12-15 | Medicine composition for treating respiratory diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510929933.3A CN105503880A (en) | 2015-12-15 | 2015-12-15 | Medicine composition for treating respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105503880A true CN105503880A (en) | 2016-04-20 |
Family
ID=55712241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510929933.3A Pending CN105503880A (en) | 2015-12-15 | 2015-12-15 | Medicine composition for treating respiratory diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105503880A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014631A (en) * | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | Tyrosine kinase inhibitors |
-
2015
- 2015-12-15 CN CN201510929933.3A patent/CN105503880A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014631A (en) * | 2008-03-03 | 2011-04-13 | 泰格尔医药科技公司 | Tyrosine kinase inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| HONG JIA ET AL.: ""Discovery of (S)‑1-(1-(Imidazo[1,2‑a]pyridin-6-yl)ethyl)-6-(1-methyl‑1H‑pyrazol-4-yl)‑1H‑[1,2,3]triazolo[4,5‑b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal−Epithelial Transition Factor (c-Met) Inhibitor in Clinical …"", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
| LIANBAO YE ET AL.: ""Design and Synthesis of Some Novel 3H-[1, 2, 3]triazolo[4, 5-d]pyrimidines as Potential c-Met Inhibitors"", 《INTERNATIONAL JOURNAL FOR PHARMACEUTICAL RESEARCH SCHOLARS》 * |
| MEHDI BAKAVOLI ET AL.: ""Molecular iodine promoted synthesis of new pyrazolo[3,4-d]pyrimidine derivatives as potential antibacterial agents"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN108403676B (en) | Application of succinic acid in improving sensitivity of bacteria to antibiotics | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| EP1609473A1 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105503880A (en) | Medicine composition for treating respiratory diseases | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105395538A (en) | Medicine composition treating acute upper respiratory infection | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105330610A (en) | Medicine composition for treating gingivitis | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| RU2179849C2 (en) | Method to treat female recurrent genital herpes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160420 |
|
| WD01 | Invention patent application deemed withdrawn after publication |